Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proton pump inhibitors to ameliorate cisplatin-induced nephrotoxicity
ChiCTR2100050436Phase 4Recruiting
- Sponsor
- Ankang People's Hospital
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of cisplatin in Nonhematologic neoplasms and Cisplatin-Induced Nephropathy (2 arms), sponsored by Ankang People's Hospital. Primary endpoint: Serum creatinine. Started May 2021; status: recruiting.
02
Drugs
cisplatin
03
Conditions
Nonhematologic neoplasmsCisplatin-Induced Nephropathy
Beyond the preview
Go deeper on ChiCTR2100050436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050436.